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ABSTRACT
This 21-week, open-label, phase 2a trial aimed to evaluate the pharmacodynamics and safety of multiple, escalating infusions of
BPS804, a neutralizing, anti-sclerostin antibody, in adults with moderate osteogenesis imperfecta (OI). Patients received BPS804
(three escalating doses each separated by 2 weeks [5, 10, and 20mg/kg]) or no treatment (reference group). The primary efﬁcacy
endpoints were mean changes from baseline to day 43 in: procollagen type 1 N-terminal propeptide (P1NP), procollagen
type 1 C-terminal propeptide (P1CP), bone-speciﬁc alkaline phosphatase (BSAP), osteocalcin (OC), and type 1 collagen cross-linked
C-telopeptide (CTX-1). Mean change from baseline to day 141 in lumbar spine areal bone mineral density (aBMD) was also assessed.
BPS804 safety and tolerability were assessed every 2 weeks. Overall, 14 adults were enrolled (BPS804 group: n¼ 9, mean age 30.7
years, mean aBMD Z-score –2.6; reference group, n¼ 5, mean age 27.4 years, mean aBMD Z-score –2.2). In the BPS804 group, P1NP,
P1CP, BSAP, and OC were increased by 84% (p< 0.001), 53% (p¼ 0.003), 59% (p< 0.001), and 44% (p¼ 0.012), respectively, versus
baseline (reference: P1NP,þ6% [p¼ 0.651]; P1CP,þ5% [p¼ 0.600]; BSAP, –13% [p¼ 0.582]; OC, –19% [p¼ 0.436]). BPS804 treatment
downregulated CTX-1 by 44% from baseline (reference: –7%; signiﬁcance was not tested for this biomarker), and increased aBMD by
4% (p¼ 0.038; reference group:þ1%; p¼ 0.138). BPS804was generally well tolerated. There were 32 adverse events reported in nine
patients; none was suspected to be treatment-related. There were no treatment-related fractures. BPS804 stimulates bone
formation, reduces bone resorption, and increases lumbar spine aBMD in adults with moderate OI. This paves the way for a longer-
term, phase 3 trial into the efﬁcacy, safety, and tolerability of BPS804 in patients with OI. © 2017 American Society for Bone and
Mineral Research.
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Introduction
Osteogenesis imperfecta (OI) is a rare genetic disorder of theconnective tissues, characterized by reduced bone mass
and bone fragility.(1) About 85% to 90% of cases are linked to
mutations in either of the two genes encoding type I collagen
(COL1A1 and COL1A2).(2,3) The remaining cases may have
mutations involving an enzyme complex responsible for
posttranslational modiﬁcations of type 1 collagen or other, as
yet unidentiﬁed, mutations.(3) OI has a prevalence of approxi-
mately 6 in 100,000 to 7 in 100,000.(2) As a result of various
collagen mutations, bone quality is reduced in patients with OI,
leading to frequent, spontaneous, and low-impact fractures,
which may cause bone deformities in the spine and limbs.(1,3)
Individuals may be affected by muscle weakness, hearing loss,
fatigue, joint laxity, scoliosis, early-onset arthritis, blue sclera,
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dentinogenesis imperfecta, and short stature.(3) Neurological
complications may also occur.(4)
Historically, the clinical classiﬁcation system, by Sillence, has
divided OI into types I to IV, although further distinct types have
recently been described.(1,2,5–7) Type I (classic non-deforming) OI
is typically a mild disease, without spine or limb deformities.
Type II (perinatal lethal) OI is very severe; most individuals die
early from respiratory failure. Type III is a progressively
deforming disease and type IV is a common variable disease
with normal sclera. The mildest form of OI (type I) accounts for
approximately one-half of the OI population.(2)
At present, there are no medical treatments for OI approved
by the US Food and Drug Administration or EuropeanMedicines
Agency. OI is managed by a combination of off-label oral or
intravenous bisphosphonates, calcium and vitamin D supple-
ments, physiotherapy, physical aids and orthotics, and correc-
tive surgery.(8–16) Thus, there is a clear need for new therapies for
patients with OI.
Sclerostin is a key negative regulator of osteoblastic bone
formation.(17) It acts on the Wnt signaling pathway, and
inhibits osteoblast differentiation and bone formation.(18) Low
levels of sclerostin have been implicated in several rare,
genetic skeletal disorders in which there is high bone mineral
density (BMD) and low fracture risk, such as sclerosteosis
(OMIM #269500) and van Buchem disease (OMIM #239100).(17)
Anti-sclerostin antibody therapy might therefore be useful for
patients with skeletal disorders that are characterized by bone
fragility, such as OI.(17) Bone remodeling has been found to be
signiﬁcantly increased in patients with OI compared with
healthy individuals,(19) which may further suggest a potential
role for anti-sclerostin antibody therapy in the management of
the disease. Such therapy has been shown to stimulate
osteoblast bone formation and improve trabecular and
cortical bone mass in a knock-in mouse model for moderately
severe OI (Brtl/þ),(20–22) as well as to reduce long-bone fragility
and increase femoral stiffness and strength.(20,21) In a murine
model of type III OI (oim/oim), anti-sclerostin antibody therapy
has been shown to reduce the number of fractures and
improve tibia cortical thickness, ultimate load, and stiff-
ness.(23,24) Treatment was also associated with signiﬁcant
increases in areal BMD (aBMD).(24) In a severe disease model of
OI, the response was less clear.(25)
BPS804 is a neutralizing, anti-sclerostin, fully human IgG2l
monoclonal antibody.(17,26) By binding to sclerostin, BPS804
alleviates the inhibitory effect of sclerostin on bone formation,
leading to the production of new bone. BPS804 received Orphan
Drug designation for OI in the United States in March 2016 and
in the European Union in June 2016.(26,27)
The primary objectives of the present randomized, open-
label, phase 2a trial were to evaluate the pharmacodynamics
and safety of multiple, escalating infusions of BPS804 in adults
withmoderate OI (OI types I, III, or IV with a history of at least two
fractures). The study included an untreated reference group to




This was a 21-week, open-label, intrapatient, dose-escalation,
phase 2a study, with a planned population of 12 to 15
individuals. Patients were randomly assigned in a 2:1 ratio to
receive BPS804 treatment or no treatment (reference group).
Randomization was performed with a validated interactive
voice response system. The study design is shown in Fig. 1.
After assessments on day 1, patients in the treatment group
were given three escalating doses of BPS804, each separated
by a 2-week period (day 1: 5mg/kg; day 15: 10mg/kg; day 29:
20mg/kg). Every 2 weeks post-dose, safety was assessed
before proceeding to the next dose level. The risks of adverse
events (AEs) were further minimized by staggering the dose
escalation so that no more than one patient was treated per
day. After the treatment period, patients were followed for
14 weeks and a study completion evaluation was carried out.
Individuals who were randomized to the untreated reference
group at screening subsequently visited the trial site only in
week 7 and at the end of the trial; during these visits,
pharmacodynamic (PD) and safety assessments were
completed.
Protocol modiﬁcations were made before patient recruitment
and are listed in the Supporting Methods.
Trial objectives
The primary efﬁcacy endpoints (PD assessments) were mean
changes from baseline to day 43 in: the serum bone formation
biomarkers procollagen type 1 N-terminal propeptide (P1NP),
procollagen type 1 C-terminal propeptide (P1CP), bone-speciﬁc
alkaline phosphatase (BSAP), and osteocalcin (OC); and the
serum bone resorption biomarker type 1 collagen cross-linked
C-telopeptide (CTX-1). Mean change from baseline to day 141 in
lumbar spine aBMD was also assessed as a primary efﬁcacy
Fig. 1. Study design. Screening took place for a maximum of 21 days prior to randomization. DXA¼dual-energy X-ray absorptiometry; EOS¼ end of
study.
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endpoint. The safety and tolerability of BPS804, administered as
multiple, dose-escalating, intravenous infusions, were also
assessed as primary endpoints.
Ethics approval
The study protocol was approved by the appropriate indepen-
dent ethics committee or institutional review board for each
center, and complied with the ethical principles of the
Declaration of Helsinki and good clinical practice. All patients
provided written informed consent.
Participants
The trial was completed at six centers in Canada, Germany,
Belgium, and the United States. Themain study inclusion criteria
were men and women aged 18 to 75 years with a diagnosis of
moderate OI (deﬁned as patients who have OI types I, III, or IV
with a history of at least two fractures), conﬁrmed by genetic
testing; a lumbar spine aBMD Z-score of –1.0 or lower and higher
than –4.0, as determined by dual-energy X-ray absorptiometry
(DXA) at screening; normal seasonal serum 25-hydroxy
vitamin D levels (25 nmol/L); and normal serum calcium levels
(8.5–10.2mg/dL [2.16–2.56mmol/L]).
Key exclusion criteria were as follows: a history of skeletal
malignancies or bone metastases, external beam radiation to
the skeleton, or hypersensitivity to monoclonal antibodies; a
history of or current diseases such as hypoparathyroidism/
hyperparathyroidism, hypothyroidism/hyperthyroidism, Paget’s
disease, conditions that required previous neck surgery
involving partial or complete thyroidectomy, or other endocrine
disorders or conditions.
Additional exclusion criteria were as follows: bone fractures in
the previous 2 weeks; suspected neural foraminal stenosis;
treatment with any antiresorptive medication, bisphosphonates,
and/or teriparatide in the 6 months before enrollment; exposure
to blood products or monoclonal antibodies in the 12 months
before initial dosing; any deformation of the spine that would
preclude proper assessment of lumbar spine aBMD by DXA
(assessed by clinical evaluation); presence of impaired renal
function as indicated by clinically signiﬁcant abnormal creatinine
or blood urea nitrogen (BUN) and/or urea values, or abnormal
urinary constituents (eg, albuminuria) at screening, and again at
visit 2 in patients randomized to the treatment group; women
whowere pregnant or lactating; and women who were planning
a pregnancy during the course of the study.
Decisions regarding discontinuation were discussed with the
sponsor on a case-by-case basis. Concomitant medications
required for treating AEs occurring between the start of
screening and the end of the trial were permitted. Administra-
tion of acetaminophen was acceptable, but was required to be
documented. For any patient who developed hypocalcemia (ie,
a serum calcium level lower than 8.2mg/dL [2.05mmol/L] or an
ionized calcium level lower than 4.4mg/dL [1.1mmol/L]),
calcium supplementation was given until calcium levels had
returned to within normal ranges.
Interventions
Patients in the treatment group received a total of three
escalating doses of intravenous BPS804 solution, each separated
by a 2-week period (day 1: 5mg/kg; day 15: 10mg/kg; day 29:
20mg/kg), at a rate of 2mL/min (total administration time
approximately 120 10min). Thirteen-week toxicology studies
in themouse (up to a maximum dose of 100mg/kg/week, which
was the no-observed-adverse-effect level) and in the cynomol-
gus monkey (up to a maximum dose of 200mg/kg/week; the
no-observed-adverse-effect level was 20mg/kg) provided
toxicology coverage for the current study. The maximum
intended dose in the current study was 20mg/kg. This dose was
equal to the maximum tested dose in a previous clinical study
(CBPS804A2101), which was well tolerated and did not raise any
overt safety concerns. Treatment was assigned to all eligible
patients in accordance with entry into the study and was
randomized using treatment allocation cards. The reference
group received no intervention at all.
Outcomes
All blood samples were collected at 8:00 a.m. (1 hour), when
patients were in a fasted state. Efﬁcacy assessments were
carried out on blood samples taken at baseline, during drug
administration (pre-dose and 2 hours post-dose), as well as on
days 8, 43, 57, 85, and 113, and at the end of the study (day
141). All assessments were measured in a central laboratory.
After collection, the blood samples were frozen and kept at
–70°C until analysis.
P1NP was measured using the Elecsys total P1NP electro-
chemiluminescence sandwich-based immunoassay with a lower
limit of quantiﬁcation (LLOQ) of 8.99 ng/mL; OC was measured
using the Elecsys N-mid OC electrochemiluminescence sand-
wich-based immunoassay with an LLOQ of 6.54 ng/mL; and CTX-
1 was measured using the Elecsys b-CrossLaps electrolumines-
cence assay with an LLOQ of 0.082 ng/mL (all assays from Roche
Diagnostics, Mannheim, Germany). P1CP was measured using
the MicroVue P1CP sandwich enzyme immunoassay with a
lower limit of detection of 1.0 ng/mL; and BSAP enzymatic
activity was measured using the MicroVue BSAP enzyme
immunoassay with a LLOQ of 4.95U/L (both assays from Quidel
Corporation, San Diego, CA, USA).
Standard pharmacokinetic (PK) parameters (the area under
the plasma concentration–time curve from time zero to the time
of the last quantiﬁable concentration [AUC0–last]; the area under
the plasma concentration–time curve from time zero to inﬁnity
[AUC0–inf]; the observed maximum plasma concentration
following drug administration [Cmax]; the time to reach Cmax
after drug administration [Tmax]; and the terminal elimination
half-life [t1/2]) were measured.
Hematology, blood chemistry, and urine analysis were
monitored for abnormalities at screening, pre-dose on each
day of treatment, 2 weeks after administration of the ﬁrst dose,
and at the end of the study. Levels of serum 25-hydroxy vitamin
D were assessed at screening only. Vital signs, physical
condition, body weight, and electrocardiography results were
assessed at screening, pre-dose on each day of treatment,
regularly during the follow-up phase, and at the end of the
study.
Electrocardiography results were also assessed 1, 2, and
5 weeks after administration of the ﬁrst dose.
All AEs and serious AEs, and their severity and suspected
relationship to the study drug, were recorded. A DXA scan was
performed at screening, 12weeks after administration of the ﬁrst
dose, and at the end of the study. The precision of this technique
has been demonstrated.(28) A radiograph was obtained only in
case of suspected fractures. If a fracture occurred in the 28 days
before the ﬁrst dose administration (treatment group) or
randomization (reference group) and the last radiograph was
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obtained more than 2 weeks before the ﬁrst administration/
randomization, radiography was repeated.
Potential immunogenicity of BPS804 was assessed in patients
who had been randomized to the treatment group. Serum anti-
BPS804 antibodies were measured using a validated homoge-
nous AlphaLISA assay with an LLOQ of 250 ng/mL (PerkinElmer
Inc., Waltham, MA, USA).
Sample size
A sample size of six patients in the BPS804 group completing the
studywas considered sufﬁcient for the simultaneous rejection of
the null hypothesis of no change from baseline (taken as the
geometric mean of screening and day 1 pre-dose values in the
BPS804 group) in the three biomarker endpoints (P1NP, P1CP,
and BSAP) or in lumbar spine aBMD.
This sample size provided >99% power to detect, at a two-
sided signiﬁcance level of 0.05, a treatment difference of at least
0.7 ng/mL in P1NP and at least 0.48mU/mL in BSAP between
baseline and day 15 after dose administration (as based on a
previous study, CBPS804A2101), assuming a variability of
0.07ng/mL for P1NP and 0.04mU/mL for BSAP. Even with
only four evaluable patients, the power would be 93% for P1NP
and 87% for BSAP. P1CP was assumed to follow a similar pattern
to P1NP.
A sample size of six patients provided 93% power to detect, at
a two-sided signiﬁcance level of 0.05, a treatment difference of
at least 0.036 g/cm2 (with a variability of 0.0004 g/cm2) in
lumbar spine aBMD between baseline and day 113 after dose
administration (as observed when measured via DXA in a
previous study, CBPS804A2101). Even with only ﬁve evaluable
patients, the power would be 84%.
A sample size of three patients in the reference group was
considered sufﬁcient for the comparison of change from
baseline between the BPS804 and reference groups. Using a
one-sided, two-sample t test at the 10% level, the power to show
a difference between groups with six patients in the BPS804
group and three patients in the reference group would be 98%
for P1NP, 97% for BSAP, and 86% for aBMD. This assumed that
the reference group would have a mean change of zero from
baseline in P1NP, BSAP, and BMD levels, and that the variability
in change from baseline would be the same as in the BPS804
group.
Study stopping rules are listed in the Supporting Methods.
Statistical analyses
The PD analysis set comprised all patients who had a baseline
measurement and at least one post-baselinemeasurement for at
least one of the biomarkers analyzed (P1NP, P1CP, BSAP, CTX-1,
and OC); a baseline measurement and at least one post-baseline
measurement for aBMD; and no major protocol deviations that
would impact on the PD data. The PK analysis set comprised all
those who had at least one post-baseline PK measurement
(Cmax, Tmax) and nomajor protocol deviations that would impact
on the PK data. The safety analysis set comprised all patients
who received the study drug.
The comparisons versus study baseline were calculated as
ratios on day 43 for P1NP, P1CP, BSAP, OC, and CTX-1 and on
day 141 for aBMD. The 90% conﬁdence intervals (CI) for the
change from study baseline were calculated (to describe the
location of true treatment difference). It was considered a
sign of efﬁcacy if patients in the BPS804 group showed
signiﬁcant increases versus baseline in P1NP, P1CP, and BSAP
on day 43 or a signiﬁcant increase in lumbar spine aBMD on
day 141 (in both cases statistical signiﬁcance was deﬁned at
p< 0.05, based on two-sided, one-sample t tests).
Summary statistics were provided for the safety assessments.
Results
Patient demographics and baseline disease
characteristics
In total, 14 adults with moderate OI were enrolled (BPS804
group, n¼ 9; reference group, n¼ 5). A patient ﬂow diagram is
shown in Fig. 2. All patients in the BPS804 group completed the
study. One patient in the reference group provided samples for
analysis of all efﬁcacy and safety assessments up until day 43 but
was subsequently lost to follow-up and therefore did not receive
a DXA scan at the end of the study. The ﬁrst patient was enrolled
on June 22, 2011; the last patient completed the study on
December 5, 2012.
Patient baseline demographics and disease characteristics are
shown in Table 1. The overall mean age wasmarginally higher in
the BPS804 group (30.7 years) than in the reference group (27.4
years). The majority of patients were men (71.4%) and all were
white. In the BPS804 group, four patients had type I OI and ﬁve
had type III/IV OI. In the reference group, two patients had type I
OI and three had type III/IV OI. Themean lumbar spine Z-score in
the BPS804 group was –2.6; in the reference group, the mean
was –2.2. Two patients in the BPS804 group and one in the
reference group had received bisphosphonates in the past; no
patient received bisphosphonates in the 2 years prior to study
entry. None of the patients in either study group was treated
with hormone replacement therapy before or during the study.
One participant in the reference group was treated with
melatonin 3mg/day, 5 days a week (for insomnia) prior to
study start; another participant in the reference group was ﬁtted
with a levonorgestrel-releasing intrauterine device before the
start of the study.
Fig. 2. Patient ﬂow diagram.
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Efficacy
Biomarkers of bone formation and bone resorption
BPS804 treatment provided signiﬁcant increases from baseline
to day 43 after ﬁrst treatment in the activity of serum biomarkers
of bone formation. P1NP was increased by 84% compared with
baseline in the BPS804 group (p< 0.001) and by 6% compared
with baseline in the reference group (p¼ 0.651; Table 2, Fig. 3A).
P1CP was increased by 53% compared with baseline in the
BPS804 group (p¼ 0.003) and by 5% compared with baseline in
the reference group (p¼ 0.600; Table 2, Fig. 3B). BSAP was
increased by 59% compared with baseline in the BPS804 group
(p< 0.001) and decreased by 13% comparedwith baseline in the
reference group (p¼ 0.582; Table 2, Fig. 3C). OC was increased
by 44% compared with baseline in the BPS804 group (p¼ 0.012)
and decreased by 19% compared with baseline in the reference
group (p¼ 0.436; Table 2, Fig. 3D).
BPS804 treatment downregulated serum levels of the bone
resorption biomarker CTX-1 by 44% frombaseline to day 43 after
ﬁrst treatment (statistical signiﬁcance was not tested). A
downregulation of 7% was observed in the reference group
(Table 2, Fig. 3E).
Lumbar spine aBMD
Treatment with BPS804 signiﬁcantly increased lumbar spine
aBMD by 4% on day 141 compared with baseline (p¼ 0.038;
ratio of geometric mean [90% CI] 1.04 [1.01 to 1.07]). In the
reference group, lumbar spine aBMD was increased by 1%
compared with baseline (p¼ 0.138; 1.01 [1.00 to 1.01]).
Pharmacokinetics
BPS804 exhibited a favorable PK proﬁle, consistent with that for
a fully human IgG2l monoclonal antibody. All nine patients
included in the PK analysis dataset had quantiﬁable serum
BPS804 concentrations throughout most of the three-period
treatment phases. Peak serum concentrations were 175mg/mL,
365mg/mL, and 746mg/mL for the 5, 10, and 20mg/kg doses,
respectively, and were reached shortly after the end of each
infusion (median Tmax of 2.12, 2.07, and 2.20 hours, respectively,
Table 1. Patient Baseline Demographics and Disease Characteristics
BPS804 (n¼ 9) Reference (n¼ 5) Total (n¼ 14)
Age (years)
Mean SD 30.7 13.5 27.4 15.5 29.5 13.7
Median (range) 25.0 (19.0 to 57.0) 21.0 (19.0 to 55.0) 21.5 (19.0 to 57.0)
Male, n (%) 7 (77.8) 3 (60.0) 10 (71.4)
White, n (%) 9 (100.0) 5 (100.0) 14 (100.0)
Type I OI, n 4 2 6
Type III/IV OI, n 5 3 8
Weight (kg)
Mean SD 61.8 14.4 58.2 13.0 60.5 13.5
Median (range) 63.9 (43.5 to 80.1) 54.0 (44.0 to 75.0) 59.5 (43.5 to 80.1)
Height (cm)
Mean SD 161.6 12.2 162.8 13.9 162.0 12.3
Median (range) 162.0 (142.0 to 178.0) 161.0 (142.0 to 176.0) 162.0 (142.0 to 178.0)
Lumbar spine Z-score
Mean SD 2.59 1.19 2.18 0.51 2.44 1.00
Median (range) 2.30 (4.9 to 1.1) 2.07 (2.9 to 1.5) 2.19 (4.9 to 1.1)
Years on bisphosphonatesa
Number of patients 2 1 3
Mean SD 8.53 4.88 15.46 10.84 5.28
Median (range) 8.53 (5.1 to 12.0) 15.46 (15.5 to 15.5) 11.99 (5.1 to 15.5)
SD¼ standard deviation; OI¼ osteogenesis imperfecta.
aNo patient had received bisphosphonates in the 2 years prior to study entry.
Table 2. Activity of Serum Bone Formation and Bone Resorption Biomarkers on Day 43 After First Treatment with BPS804
BPS804 (n¼ 9) Reference (n¼ 5)
Parameter








P1NP 1.84 (1.65–2.06) 84 <0.001 1.06 (0.83–1.34) 6 0.651
P1CP 1.53 (1.27–1.84) 53 0.003 1.05 (0.87–1.26) 5 0.600
BSAP 1.59 (1.36–1.86) 59 <0.001 0.87 (0.53–1.42) 13 0.582
OC 1.44 (1.17–1.78) 44 0.012 0.81 (0.48–1.36) 19 0.436
CTX-1a 0.554 () 44 NT 0.932 () 7 NT
CI¼ conﬁdence interval; P1NP¼procollagen type 1 N-terminal propeptide; P1CP¼procollagen type 1 C-terminal propeptide; BSAP¼bone-speciﬁc
alkaline phosphatase; OC¼ osteocalcin; CTX-1¼ type 1 collagen cross-linked C-telopeptide; NT¼not tested.
aFor CTX-1, n¼ 8; 90% CI values and p values were not determined for CTX-1.
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for the three doses). Summary statistics of PK parameters are
presented in Table 3.
Safety
BPS804 was generally well tolerated. Table 4 shows the number
of patients affected for each category of AE. There were 32
different AEs reported overall (Supporting Table 1; 22 different
AEs were reported in the BPS804 group and 13 were reported in
the reference group); none was suspected by the investigators
to be related to BPS804. Three AEs (occurring in two patients
receiving BPS804) weremoderate in intensity; the remaining AEs
were mild in intensity. Headache, inﬂuenza, arthralgia, and
fatigue were the most common AEs in both groups (Supporting
Table 1). There were no deaths reported in the study. There were
no serious AEs reported in the BPS804 treatment group. One
serious AE (goiter) was reported in the reference group, which
was mild in intensity and was resolved before the end of the
study. The goiter was euthyroid and the patient was hospitalized
on the same day as the event occurred and treated with
radioiodine therapy. The event was not suspected to be related
to the study medication by the study investigator. No other
clinically relevant AEs were reported. No abnormal serum
calcium level changes, or clinically signiﬁcant changes in
chemistry parameters (including creatinine), were observed.
Fractures were reported in three patients receiving BPS804 (one
fracture per patient, in the ankle [minor avulsion of the right
malleolus sustained when the patient jumped down a ﬂight of
stairs], foot, and scapula, respectively; Supporting Table 1); all
were deemed unrelated to BPS804 and not clinically signiﬁcant.
Of those fractures, two occurred 2 days after the ﬁrst BPS804
dose and the third one occurred on day 48, before aBMD levels
had reached their peak amplitude. No fractures were reported in
Fig. 3. Changes from baseline to week 20 in (A–D) serum levels of bone formation and (E) bone resorption biomarkers in the BPS804 group and the
reference group. P1NP, P1CP, OC, and CTX-1 were measured in ng/mL; BSAP was measured in mU/mL. BSAP¼bone-speciﬁc alkaline phosphatase; CTX-
1¼ type 1 collagen cross-linked C-telopeptide; OC¼ osteocalcin; P1CP¼procollagen type 1 C-terminal propeptide; P1NP¼procollagen type 1
N-terminal propeptide.
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the reference group; although based on medical histories, all
patients had had previous fractures. Given the short duration of
the study and the small sample size, the clinical signiﬁcance of
this observation is unclear, and may be a chance ﬁnding.
Antibodies to BPS804 were detected in the serum of ﬁve
patients receiving BPS804; of these, four patients tested positive
for antibodies to BPS804 at baseline, before dosing.
Discussion
BPS804, administered as intravenous infusions at doses of 5, 10,
and 20mg/kg, signiﬁcantly increased biomarkers of bone
formation; the results were consistent with a gain in bone
mass, as demonstrated by the signiﬁcant increase in lumbar
spine aBMD.
The primary objectives of this phase 2a trial were to determine
the pharmacodynamics (as shown by changes from baseline to
day 43 in serum biomarkers of bone formation and resorption,
and changes from baseline to day 141 in lumbar spine aBMD),
and to evaluate the PK proﬁle, safety, and tolerability of three
intrapatient escalating doses of BPS804 in adults with moderate
OI. An untreated reference group was included for monitoring
and observation of the natural progression of OI.
P1NP, P1CP, BSAP, and OC are widely used markers of bone
formation.(29) Antiresorptive treatment with bisphosphonates is
associated with an increase in aBMD and a reduction in bone
formation and resorption biomarkers.(10,30–32) In contrast,
treatment with BPS804 increased bone formation biomarkers
(P1NP, P1CP, BSAP, and OC) and decreased the bone resorption
biomarker CTX-1. These results are consistent with published
data on osteoanabolic responses using anti-sclerostin anti-
bodies for the treatment of postmenopausal osteoporosis.(33,34)
BPS804 exhibited a predictable PK proﬁle, as would be
expected for a fully human IgG2 monoclonal antibody binding
to a soluble ligand. Four patients tested positive for antibodies
to BPS804 at baseline, before dosing. This ﬁnding is not readily
explained, but likely indicates an underperforming assay.
In this study, BPS804 was generally well tolerated, with only
mild or moderate AEs reported. Three fractures were reported in
the BPS804 group, all of which were deemed unrelated to
treatment. No fractures were reported in the reference group.
Whether the increase in aBMD observedwill result in a reduction
in the fracture incidence needs to be investigated in larger and
longer-term trials.
This trial demonstrates that BPS804 treatment stimulates
bone formation and reduces bone resorption in adults with
moderate OI and is associated with an increase in lumbar
spine aBMD. BPS804 interferes with Wnt signaling by binding
to the inhibitory component sclerostin, thereby producing an
osteoanabolic response. A limitation of the study was the
small number of participants; further studies enrolling a
larger cohort of patients with OI are warranted to conﬁrm
these data.
Current treatment concepts in OI rely primarily on bi-
sphosphonates, which enhance mechanical properties and
bone architecture on a macroscale by reducing cortical porosity
and improving cortical thickness and bone width. This leads to
reduced bone resorption and bone turnover.(35) However, it is
still unclear whether the effects of bisphosphonates on bone
metabolism are favorable for bone regeneration and bone
Table 3. Pharmacokinetic Parameters for BPS804
Parameter BPS804 5mg/kg (n¼ 9) BPS804 10mg/kg (n¼ 9) BPS804 20mg/kg (n¼ 9)
AUC0–last (daymg/mL) 604.2 160.0 ND 8458.3 2512.5
AUC0–inf (daymg/mL) ND ND 8541.7 2533.3
Cmax (mg/mL) 175 34 365 86 746 169
Tmax (hours), median (min–max) 2.12 (1.95–4.18) 2.07 (1.97–2.38) 2.20 (2.00–11.1)
t1/2 (days) ND ND 9.58 1.39
Data shown are mean SD unless otherwise indicated.
AUC0–last¼ area under the plasma concentration–time curve from time zero to the time of the last quantiﬁable concentration; ND¼not done;
AUC0–inf¼ area under the plasma concentration–time curve from time zero to inﬁnity; Cmax¼ observed maximum plasma concentration following drug
administration; Tmax¼ time to reach Cmax after drug administration; t1/2¼ terminal elimination half-life; SD¼ standard deviation.
Table 4. Incidence of Adverse Events in the BPS804 Treatment Group and the Reference Group by Primary System Organ Class
Adverse event BPS804 (n¼ 9) Reference (n¼ 5) Total (n¼ 14)
Total 9 (100) 4 (80.0) 13 (92.9)
Infections and infestations 3 (33.3) 2 (40.0) 5 (35.7)
Injury, poisoning, and procedural complications 5 (55.6) 0 5 (35.7)
General disorders and administration site conditions 3 (33.3) 1 (20.0) 4 (28.6)
Nervous system disorders 2 (22.2) 2 (40.0) 4 (28.6)
Musculoskeletal and connective tissue disorders 2 (22.2) 1 (20.0) 3 (21.4)
Gastrointestinal disorders 1 (11.1) 1 (20.0) 2 (14.3)
Respiratory, thoracic, and mediastinal disorders 2 (22.2) 0 2 (14.3)
Endocrine disorders 0 1 (20.0) 1 (7.1)
Psychiatric disorders 0 1 (20.0) 1 (7.1)
Reproductive system and breast disorders 0 1 (20.0) 1 (7.1)
Values are n (%).
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material properties on a molecular level, particularly when
considering the need for long-term treatment regimens.
Furthermore, the apparent signiﬁcant decrease in the incidence
of fractures associated with bisphosphonates remains a matter
of debate.(36–40) Hence, the bone-remodeling-based concept of
anti-sclerostin treatment may provide a promising approach to
cover relevant treatment periods as part of a long-term
medication strategy that enables phases of bone regeneration
and formation. The ﬁndings of this study pave the way for a
longer-term, phase 3 trial to assess the efﬁcacy, safety, and
tolerability of BPS804 in patients with OI.
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